Navigating Complexity > Steering Decisions > Building Solutions

TCR T-cell Therapies: What if Magic Bullets Simply Aren't Good Enough?

On the heels of a recent post in which I discussed evolving dynamics and strategic implications underscoring different types of allogeneic cell therapies in oncology, I find it fitting to address another substantive consideration in the field, that of targeting moieties.

Donor-derived T-cells vs. iPSC- and Cord-derived NKs: Allo Not Created Equal

A common question I get from my cancer cell therapy clients at Cello Health BioConsulting is why, despite the lion share of clinical data in support of T-cell therapies, it is NK cell therapy candidates (iPSC- and cord-derived) that seem of late to be capturing so much more enthusiasm from investors and Pharma these days?The answer has to do in large part with the risk-averse nature of Pharma, which in this case has been laudable.

Different perspectives on the Burden of Disease

What do medical market research and health economic outcomes research have in common? How can we combine our work on burden of disease in a way which realises it fullest potential? What can we learn from each other’s approach?Our starting pointAs we became acquainted with the work of our colleagues in the Health Economic Outcomes research world, we came to realise that we overlapped in areas of research with patients, but that in other fundamental ways we were differing – for example in our.

Are We Nearing the Plateau of Productivity for in-vivo Therapeutic Gene Editing?

Amidst success of in vivo adeno-associated virus (AAV) based gene therapies, the gene therapy community awaits key outcomes from next month’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) meeting discussing toxicities and deaths associated with high titer AAV dosing and potential long-term adverse events.